India flags Abhayrab batch as substandard
Analysis based on 14 articles · First reported Sep 04, 2026 · Last updated Sep 05, 2026
The regulatory action could undermine confidence in Indian Immunologicals' vaccine quality, potentially affecting its domestic market share and export reputation. The company may face increased scrutiny and potential financial losses if the batch is confirmed spurious, though the immediate impact is limited as the company has not responded and the investigation is ongoing.
India's drug regulator, the India — Central Drugs Standard Control Organisation, has flagged a batch of the rabies vaccine Abhayrab, manufactured by Indian Immunologicals Limited, as substandard and potentially spurious after it failed a potency test. The action, detailed in an August 27 letter from Drugs Controller General Rajeev Singh Raghuvanshi to state regulators, followed a finding by the India — Central Drugs Laboratory in Kasauli that a field sample of batch KE25012 did not meet potency requirements and was classified as 'not of standard quality' and 'misbranded'. The laboratory also noted significant discrepancies in labelling, artwork, QR code verification, cap colour, licence details, and packaging text compared to a retained reference sample, raising concerns about the sample's identity and authenticity. The regulator has ordered an investigation into whether the batch could be a spurious drug under India's Drugs and Cosmetics Act. This is the second such incident in less than two years; in January 2025, Indian Immunologicals had notified the regulator about counterfeit Abhayrab doses bearing batch number KA24014, which led to alerts from health authorities in the United States, United Kingdom, and Australia for travellers who may have received the vaccine in India. Indian Immunologicals has supplied over 210 million doses of Abhayrab over two decades and holds a 40% share of the domestic rabies vaccine market. The company exports to more than 40 countries, including South Africa, Turkey, Vietnam, Cambodia, Zimbabwe, Thailand, and the United Arab Emirates. The government document does not state how many doses of the flagged batch were distributed or whether any were exported.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard